



## Research on Invasive Clinical Cardiology - ICCI-PAZ Group

Publications:

72

Q1:

43



### RESEARCH ACTIVITY

#### ■ Doctoral theses

**del Prado Díaz S.** Cambios hemodinámicos y adaptación morfológica y funcional del corazón materno durante la gestación única y gemelar [dissertation]. Madrid: UAM; 2021(17/05/2021).

**Directors:** de la Calle Fernández-Miranda M., Guzmán Martínez G.


#### ■ Publications

- Alfonso F, Cuesta J, del Blanco BG, Bosa F, de Prado AP, Masotti M, Trillo R, Rumoroso JR, Moreno R, Cequier A, Gutiérrez H, Touchard AG, López-Minguez JR, Zueco J, Serra A, Velázquez M, Moris C, Bastante T, García-Guimaraes M, Rivero F, Fernández-Pérez C. Scoring balloon predilation before bioresorbable vascular scaffold implantation in patients with in-stent restenosis: the RIBS VI 'scoring' study. *Coronary Artery Dis.* 2021; 32(2): 96-104. Article. IF: 1.717; Q4
- Anker SD, Butler J, Filippatos G, Ferreira JP, Boc-

- chi E, Bohm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiuire-Valenzuela E, Giannetti N, Gómez-Mesa JE, Janssens S, Januzzi JL, González-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Pina IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinearano D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaadt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M, (López-Sendón JL). Empagliflozin in heart failure with a preserved ejection fraction. *New Engl J Med.* 2021; 385(16): 1451-61. Article. IF: 176.079; D1
- Anker SD, Butler J, Filippatos G, Khan MS, Marx N, Lam CSP, Schnaadt S, Ofstad AP, Brueckmann M, Jamal W, Bocchi EA, Ponikowski P, Perrone SV, Januzzi JL, Verma S, Bohm M, Ferreira JP, Pocock SJ, Zannad F, Packer M. Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status results from the EMPEROR-Reduced Trial. *Circulation.* 2021; 143(4): 337-49. Article. IF: 39.918; D1
- Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE,



- Kosiborod MN, Cherney DZ, Dwyer JP, Scirica BM, Bailey CJ, Diaz R, Ray KK, Udell JA, Lopes RD, Lapuerta P, Steg PG, (López-Sendón JL). Sotagliflozin in patients with diabetes and chronic kidney disease. *New Engl J Med.* 2021; 384(2): 129-39. Article. IF: 176.079; D1
- Briongos-Figuero S, García-Alberola A, Rubio J, Segura JM, Rodríguez A, Peinado R, Alzueta J, Martínez-Ferrer JB, Vinolas X, de la Concha JF, Anguera I, Martín M, Cerdá L, Pérez L. Long-term outcomes among a nationwide cohort of patients using an implantable cardioverter-defibrillator: UMBRELLA Study Final Results. *J Am Heart Assoc.* 2021; 10(1): e018108. Article. IF: 6.106; Q2
  - Caro-Codón J, Lip GYH, Rey JR, Iniesta AM, Rosillo SO, Castrejón-Castrejón S, Rodríguez-Sotelo L, García-Veas JM, Marco I, Martínez LA, Martín-Polo L, Merino C, Martínez-Cossiani M, Buno A, González-Valle L, Herrero A, López-de-Sa E, Merino JL. Prediction of thromboembolic events and mortality by the CHADS(2) and the CHA(2) DS(2)-VASc in COVID-19. *Europace.* 2021; 23(6): 937-47. Article. IF: 5.486; Q2
  - Caro-Codón J, Rey JR, Buño A, Iniesta AM, Rosillo SO, Castrejón-Castrejón S, Merino C, Marco I, Martínez LA, García-Veas JM, Martín-Polo L, Rodríguez-Sotelo L, Martínez-Cossiani M, González-Valle L, Herrero A, López-de-Sa E, Merino JL. Characterization of myocardial injury in a cohort of patients with SARS-CoV-2 infection. *Med Clin-Barcelona.* 2021; 157(6): 274-80. Article. IF: 3.2; Q2
  - Caro-Codón J, Rey JR, Buño A, Iniesta AM, Rosillo SO, Castrejón-Castrejón S, Rodríguez-Sotelo L, Martínez LA, Marco I, Merino C, Martín-Polo L, García-Veas JM, Martínez-Cossiani M, González-Valle L, Herrero A, López-de-Sa E, Merino JL. Characterization of NT-proBNP in a large cohort of COVID-19 patients. *Eur J Heart Fail.* 2021; 23(3): 456-64. Article. IF: 17.349; D1
  - Chieffo A, Tarantini G, Naber CK, Barbato E, Roffi M, Stefanini GG, Buchanan GL, Buszman P, Moreno R, Zawislak B, Cayla G, Danenberg H, Da Silveira JAB, Nef H, James SK, Ferre JM, Voskuil M, Witt N, Windecker S, Baumbach A, Dudek D. Performing elective cardiac invasive procedures during the COVID-19 outbreak: a position statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eurointervention.* 2021; 16(14): 1177-86. Article. IF: 7.728; Q1
  - de Groot JR, Weiss TW, Kelly P, Monteiro P, Deharo JC, de Asmundis C, López-de-Sa E, Waltenberger J. 2021; 42(28): 2765-75. Review. IF: 35.855; D1
  - Gao C, Kogame N, Sharif F, Smits PC, Tonino P, Hofma S, Moreno R, Choudhury A, Petrov I, Cequier A, Colombo A, Kaul U, Zaman A, de Winter RJ, Onuma Y, Serruys PW. Prospective multicenter randomized all-comers trial to assess the safety and effectiveness of the ultra-thin strut sirolimus-eluting coronary stent supraflex two-year outcomes of the TALENT Trial. *Circ Cardiovasc Inte.* 2021; 14(3): e010312. Letter. IF: 7.514; Q1
  - García-Escobar A, Jiménez-Valero S, Galeote G, Jurado-Román A, García-Rodríguez J, Moreno R. The soluble catalytic ectodomain of ACE2 a biomarker of cardiac remodelling: new insights for heart failure and COVID19. *Heart Fail Rev.* 2021; 26(4): 961-71. Article. IF: 4.654; Q2
  - García-Escobar A, Jurado-Román A, Jiménez-Valero S, Galeote G, Moreno R. Clinical outcomes of drug-eluting balloon for treatment of small coronary artery in patients with acute myocardial infarction: comment. *Intern Emerg Med.* 2021; 16(4): 1099-100. Letter. IF: 5.472; Q2
  - García-Gimaraes M, Bastante T, Macaya F, Roura G, Sanz R, Alvarado JCB, Tizón H, Flores-Ríos X, Moreu J, Ojeda S, Nogales JM, Veiga G, Massotti M, Camacho-Freire SJ, Jiménez-Valero S, Jiménez-Kockar M, Lozano I, González-Ferreiro R, Velazquez M, Avanzas P, Rivero F, Alfonso F. Spontaneous coronary artery dissection in Spain: clinical and angiographic characteristics, management, and in-hospital events. *Rev Esp Cardiol.* 2021; 74(1): 15-23. Article. IF: 6.975; Q1
  - Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Turgeon AF, Kornblith LZ, Kahn SR, Marshall JH, Kim KS, Houston BL, Derde LPG, Cushman MC, Tritschler T, Angus DC, Godoy LC, McQuilten Z, Kirwan BA, Farkouh ME, Brooks MM, Lewis RJ, Berry LR, Lorenzi E, Gordon AC, Berry SM, McArthur CJ, Neal MD, Hochman JS, Webb SA, Zarychanski R, Ahuja T, Al-Beidh F, Annane D, Arabi YM, Aryal D, Kreuziger LB, Beane A, Bihanić Z, Bihari S, Billett HH, Bond L, Bonten M, Brunkhorst F, Buxton M, Buzgau A, Castellucci LA, Chekuri S, Chen JT, Cheng AC, Chkhikvadze T, Coiffard B, Contreras A, Costantini TW, de Brouwer S, Detry MA, Duggal A, Dzavik V, Effron MB, Eng HF, Escobedo J, Estcourt LJ, Everett BM, Ferguson DA, Fitzgerald M, Fowler RA, Froess JD, Fu ZX, Galanaud JP, Galen BT, Gandotra S, Girard TD, Goodman AL, Goossens H, Green C, Greenstein YY, Gross PL, Haniffa R, Hegde SM, Hendrickson CM, Higgins AM, Hindenburg AA, Hope AA, Horowitz JM, Horvat



CM, Huang DT, Hudock K, Hunt BJ, Husain M, Hyzy RC, Jacobson JR, Jayakumar D, Keller NM, Khan A, Kim Y, Kindzelski A, King AJ, Kornblith AE, Kutcher ME, Laffan MA, Lamontagne F, Le Gal G, Leeper CM, Leifer ES, Lim G, Lima FG, Linstrum K, Litton E, López-Sendón J, Loher SA, Marten N, Martinez AS, Martínez M, García EM, Mavromichalis S, McAuley DF, McDonald EG, McGlothlin A, McGuinness SP, Middeldorp S, Montgomery SK, Mouncey PR, Murthy S, Nair GB, Nair R, Nichol AD, Nicolau JC, Nunez-García B, Park JJ, Park PK, Parke RL, Parker JC, Parnia S, Paul JD, Pompilio M, Quigley JG, Rosenson RS, Rost NS, Rowan K, Santos FO, Santos M, Santos MO, Satterwhite L, Saunders CT, Schreiber J, Schutgens REG, Seymour CW, Siegal DM, Silva DG, Singh AB, Slutsky AS, Solvason D, Turner AM, Van Bentum-Puijk W, van de Veerdonk FL, van Diepen S, Vázquez-Grande G, Wahid L, Wareham V, Widmer RJ, Wilson JG, Yuriditsky E, Zhong YQ. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. *New Engl J Med.* 2021; 385(9): 777-89. Article. IF: 176.079; D1

- Gonzalo N, Salazar CH, Pérez-Vizcayno MJ, Gómez-Polo JC, Jiménez-Quevedo P, Jiménez-Valero S, Masotti M, Romaguera R, Fernández-Ortiz A, Escaned J, Alfonso F, Macaya C. Influence of neatherosclerosis on prognosis and treatment response in patients with in-stent restenosis. *Rev Esp Cardiol.* 2021; 74(5): 427-35. Article. IF: 6.975; Q1
- González-García A, Jiménez-Valero S, Jurado-Román A, Galeote G, Moreno R. Transcatheter aortic valve implantation during COVID-19 pandemic: The device also matters. *Cardiovasc Revasc Med.* 2021; 26: 66-7. Letter. Not Indexed
- Grand J, Miger K, Sajadieh A, Kober L, Torp-Pedersen C, Ertl G, López-Sendón J, Maggioni AP, Teerlink JR, Sato N, Gimpelewicz C, Metra M, Holbro T, Nielsen OW. Systolic blood pressure and outcome in patients admitted with acute heart failure: An analysis of individual patient data from 4 randomized clinical trials. *J Am Heart Assoc.* 2021; 10(18): e022288. Article. IF: 6.106; Q2
- Gutiérrez E, Gómez-Lara J, Moreno R. Importance of nonobstructive atheromatosis in patients with acute myocardial infarction. *Rev Esp Cardiol.* 2021; 74(11): 901-4. Editorial Material. IF: 6.975; Q1
- Hernández JM, Otaegui I, Subinas A, Gómez-Menchero A, Moreno R, Rondan J, Muñoz-García E, Sainz-Laso F, del Blanco BG, Rumoroso



- JR, Díaz JF, Berenguer A, Gómez-Lara J, Zueco J. First-in-man evaluation of a sirolimus-eluting stent with abluminal fluoropolymeric/trifusral coating with ultrathin struts by OCT at 9 months' follow-Up: The PROMETHEUS Study. *Cardiovasc Revasc Med.* 2021; 32: 18-24. Article. Not Indexed
- Jurado-Román A, González A, Jiménez-Valero S, Galeote G, Moreno R, de Sa EL. What have we learnt from the use of papyrus covered stent in France and Spain?. *Catheter Cardio Inte.* 2021; 98(2): 410. Letter. IF: 2.585; Q3
  - Jurado-Román A, Jiménez-Valero S, Galeote G, Moreno R. Traveling wire after chronic total occlusion percutaneous coronary intervention. *J Invasive Cardiol.* 2021; 33(7): E578-9. Editorial Material. IF: 1.711; Q4
  - Jurado-Román A, Rodríguez O, Amat I, Romani SA, García-Touchard A, Cruz-González I, Benito-González T, Fernández-Cisnal A, Córdoba-Soriaño JG, Subinas A, Hernández-Antolín R, Bayón J, García-Tejada J, Salinas P, Cortés C, Lozano F, Bastante T, Núñez-Gil IJ, Moreno R, López-Sendón JL. Clinical outcomes after implantation of polyurethane-covered cobalt-chromium stents: Insights from the papyrus-Spain registry. *Cardiovasc Revasc Med.* 2021; 29: 22-8. Article. Not Indexed
  - Lam CSP, Giczevska A, Sliwa K, Edelmann F, Refsgaard J, Bocchi E, Ezekowitz JA, Hernández AF, O'Connor CM, Roessig L, Patel MJ, Pieske B, Anstrom KJ, Armstrong PW, (López-Sendón JL). Clinical outcomes and response to vericiguat according to index heart failure event insights from the VICTORIA Trial. *JAMA Cardiol.* 2021; 6(6): 706-12. Article. IF: 30.154; D1
  - Lawler PR, Goligher EC, Berge JS, Neal MD, McVerry BJ, Nicolau JC, Gong MN, Carrier M, Rosenson RS, Reynolds HR, Turgeon AF, Escobedo J, Huang DT, Bradbury CA, Houston BL, Kornblith LZ, Kumar A, Kah NSR, Cushman M, McQuilton Z, Slutsky AS, Kim KS, Gordon AC, Kirwan BA, Brooks MM, Higgins AM, Lewis RJ, Lorenzi E, Berry SM, Berry LR, Angus DC, McArthur CJ, Webb SA, Farkouh ME, Hochman JS, Zarychanski R, Aday AW, Al-Beidh F, Annane D, Arabi YM, Aryal D, Kreuziger LB, Beane A, Bhimani Z, Bihari S, Billetti HH, Bond L, Bontem M, Brunkhorst F, Buxton M, Buzgau A, Castellucci LA, Chekuri S, Chen JT, Cheng AC, Chkhikvadze T, Coiffard B, Costantini TW, de Brouwer S, Derde LPG, Detry MA, Duggal A, Dzavil V, Effron MB, Escourt LJ, Everett BM, Ferguson DA, Fitzgerald M, Fowler RA, Galanaud JP, Galen BT, Gandotra S, García-Madrona S, Girard TD, Godoy LC, Goodman AL, Goossens H, Green C, Greenstein YY, Gross PL, Hamburg NM, Haniffa R, Hanna G, Hanna N, Heggde SM, Hendrickson CM, Hite RD, Hindenburg AA, Hope AA, Horowitz JM, Horvat CM, Hudock K, Hunt BJ, Husain M, Hyzy RC, Iyer VN, Jacobson JR, Jayakumar D, Keller NM, Khan A, Kim Y, Kindzelski AL, Kin AJ, Knudson MM, Kornblith AE, Krishnan V, Kutcher ME, Laffan MA, Lamontagne F, Le Gal G, Leeper CM, Leifer ES, Lim G, Lima FG, Linstrum K, Litton E, López-Sendón J, Moreno JLLS, Lother SA, Malhotra S, Marcos M, Martinez AS, Marshall JC, Marten N, Matthay MA, McAuley DF, McDonald EG, McGlothlin A, McGuinness SP, Middeldorp S, Montgomery SK, Moore SC, Guererro RM, Mouncey PR, Murthy S, Nair GB, Nair R, Nichol AD, Núñez-García B, Pandey A, Park PK, Parker RL, Parker JC, Parnia S, Paul JD, González YSP, Pompilio M, Prekker ME, Quigley JG, Rost NS, Rowan K, Santos FO, Santos M, Santos MO, Satterwhite L, Saunders CT, Schutgens REG, Seymour CW, Siegal DM, Silva DG, Shankar-Hari M, Sheehan JP, Singh AB, Solvason D, Stanworth SJ, Tritschler T, Turner AM, Van Bentum-Puijk W, van de Veerdonk FL, van Diepen S, Vázquez-Grande G, Wahid L, Wareham V, Wells BJ, Widmer RJ, Wilson JG, Yuriditsky E, Zampieri FG. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. *New Engl J Med.* 2021; 385(9): 790-802. Article. IF: 176.079; D1
  - López-de-Sa E. Acute coronary occlusion in non-STEMI: If you change the way you look at things, the things you look at change. *Int J Cardiol.* 2021; 322: 49-50. Editorial Material. IF: 4.039; Q2
  - López-Sendón J, Moreno R, Tamargo J. ISCHEMIA trial: key questions and answers. *Eur Cardiol.* 2021; 16: e34. Article. Not Indexed
  - Magnani G, Ardissino D, Im K, Budaj A, Storey RF, Steg PG, Bhatt DL, Cohen M, Ophius TO, Goudeven A, Parkhomenko A, Kamensky G, Angiolillo DJ, López-Sendón J, Johanson P, Braunwald E, Sabatine MS, Bonaca MP. Predictors, type, and impact of bleeding on the net clinical benefit of long-term ticagrelor in stable patients with prior myocardial infarction. *J Am Heart Assoc.* 2021; 10(4): e017008. Article. IF: 6.106; Q2
  - Mancini G BJ, Leipsic J, Budoff MJ, Hague CJ, Min JK, Stevens SR, Reynolds HR, O'Brien SM, Shaw LJ, Manjunath CN, Mavromatis K, Demkow M, López-Sendón JL, Chernavskiy AM, Gosselin G, Schuchlenz H, Devlin GP, Chauhan A, Bangalore S, Hochman JS, Maron DJ. CT angiography followed by invasive angiography in patients with moderate or severe ischemia-insights from the ISCHEMIA Trial. *JACC Cardiovasc Imaging.* 2021; 14(7): 1384-93. Article. IF: 16.051; D1
  - Manolis AJ, Boden WE, Collins P, Dechend R, Kallistratos MS, Sendón JL, Poulimenos LE, Ambrosio G, Rosano G. State of the art approach to managing angina and ischemia: tailoring treatment to the evidence. *Eur J Intern Med.* 2021; 92: 40-7. Review. IF: 7.749; Q1
  - Melón NMM, Valero SJ, González-Trevilla AA, Martín MTV. Intraplaque hemorrhage: Can OCT identify this elusive pathological substrate? *Cardiovasc Revasc Med.* 2021; 30: 89-90. Editorial Material. Not Indexed
  - Merino-Caviedes S, Gutiérrez LK, Alfonso-Almazán JM, Sanz-Estebáñez S, Cordero-Grande L, Quintanilla JG, Sánchez-González J, Marina-Breyesse M, Galán-Arriola C, Enríquez-Vázquez D, Torres C, Pizarro G, Ibáñez B, Peinado R, Merino JL, Pérez-Villacastín J, Jalife J, López-Yunta M, Vázquez M, Aguado-Sierra J, González-Ferrer JJ, Pérez-Castellano N, Martín-Fernández M, Alberola-López C, Filgueiras-Rama D. Time-efficient three-dimensional transmural scar assessment provides relevant substrate characterization for ventricular tachycardia features and long-term recurrences in ischemic cardiomyopathy. *Sci Rep-Uk.* 2021; 11(1): 18722. Article. IF: 4.996; Q2
  - Mesnier J, Ducrocq G, Danchin N, Ferrari R, Ford I, Tardif JC, Tendera M, Fox KM, Steg PG, (López-Sendón JL). International observational analysis of evolution and outcomes of chronic stable angina the multinational CLARIFY study. *Circulation.* 2021; 144(7): 512-23. Article. IF: 39.918; D1
  - Miller AB, Januzzi JL, O'Neill BJ, Gundapaneni B, Patterson TA, Sultan MB, López-Sendón J. Causes of cardiovascular hospitalization and death in patients with transthyretin amyloid cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]). *Am J Cardiol.* 2021; 148: 146-50. Article. IF: 3.133; Q3
  - Monreal E, de la Maza SS, Gullón P, Natera-Villalba E, Chico-García JL, Beltrán-Corbellini A, Martínez-Sanz J, García-Barragán N, Buisan J, Toledo R, Alonso-Canovas A, Pérez-Torre P, Matute-Lozano MC, López-Sendón JL, García-Ribas G, Corral I, Fortun J, Montero-Errasquin B, Manzano L, Maiz-Carreño L, Costa-Frossard L, Masjuan J. Non-severe immunosuppression might be associated with a lower risk of moderate-severe acute respiratory distress syndrome in COVID-19: A pilot study. *J Med Virol.* 2021; 93(4): 2243-51. Article. IF: 20.693; D1
  - Moreno R, Alonso JJ, Caballero R, del Corral E, Elizaga J, Asenjo RM, Mena MJ, Alfonso F, Fernández-Ortiz A, Goicoechea FJ, Botas J, Navarro F, Alegria-Barrero E, Ansede JC, de Sa EL, López-Sendón JL. Age and gender influence on time of arrival for STEMI patients during Covid-19 pandemic. *Am J Emerg Med.* 2021; 42: 244-5. Letter. IF: 4.093; Q1
  - Moreno R, Baz JA, Moreu J, Berenguer A, González-García A, Galeote G, Hernández U, Cantón T, Jiménez-Valero S, Jurado-Román A, Moya H, Lazaro E. Transcatheter aortic valve implantation for degenerated aortic valves: Experience with a new supra-annular device. The Spanish Allegra valve-in-valve (SAVIV) registry. *Catheter Cardio Inte.* 2021; 98(2): 365-70. Article. IF: 2.585; Q3
  - Moreno R, Díez JL, Diarte JA, Salinas P, Hernández JMD, Andrés-Cordón JF, Trillo R, Briales JA, Amat-Santos I, Romaguera R, Díaz JF, Vaquerizo B, Ojeda S, Cruz-González I, Morena-Salas D, de Prado AP, Sarnago F, Portero P, Gutiérrez-Barrios A, Alfonso F, Bosch E, Pinar E, Ruiz-Arroyo JR, Ruiz-Quevedo V, Jiménez-Mazuecos J, Lozano F, Rumoroso JR, Novo E, Irazusta FJ, Del Blanco BG, Moreu J, Ballesteros-Pradas SM, Frutos A, Villa M, Alegria-Barrero E, Lazarro R, Paredes E. Impact of diabetes in patients waiting for invasive cardiac procedures during COVID-19 pandemic. *Cardiovasc Diabetol.* 2021; 20(1): 69. Article. IF: 8.949; Q1
  - Moreno R, Unverdorben M, Jurado-Roman A, Galeote G, Jiménez-Valero S, Arroyo-Ucar E, Thiele H. The risk of valve thrombosis is higher with intra-annular versus supra-annular transcatheter aortic valve prosthesis. A meta-analysis from randomized controlled trials. *Clin Res Cardiol.* 2021; 110(12): 2007-9. Letter. IF: 6.138; Q2
  - Moreno R. After TAVI, aspirin vs. aspirin plus clopidogrel for 3 mo reduced bleeding and a composite of bleeding and thrombotic events at 1 y. *Ann Intern Med.* 2021; 174(2): JC21. Editorial Material. IF: 51.598; D1
  - Ntaios G, Huisman MV, Diener HC, Halperin JL, Teutsch C, Marler S, Gurusinghe VK, Thompson M, Lip GYH, Olshansky B, (López-Sendón JL). Anticoagulant selection in relation to the SAME-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry. *Hell J Cardiol.* 2021; 62(2): 152-7. Article. IF: 5.795; Q2
  - Oliver JM, Gallego P, González AE, Ávila P, Alonso A, García-Hamilton D, Peinado R, Dos-Subira L, Pijuan-Domenech A, Rueda J, Rodríguez-Pu-



- ras MJ, García-Orta R, Martínez-Quintana E, Dattino T, Fernández-Aviles F, Bermejo J. Predicting sudden cardiac death in adults with congenital heart disease. *Heart*. 2021; 107(1): 67-75. Article. IF: 7.365; Q1
- Oliver-Ruiz JM, Peinado-Peinado R. Preventing ventricular arrhythmias and sudden cardiac death in adults with repaired tetralogy of Fallot: a never-ending story? *Rev Esp Cardiol*. 2021; 74(11): 905-8. Editorial Material. IF: 6.975; Q1
  - Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Sattar N, Brueckmann M, Jamal W, Cotton D, Iwata T, Zannad F. Empagliflozin in patients with heart failure, reduced ejection fraction, and volume overload. *J Am Coll Cardiol*. 2021; 77(11): 1381-92. Article. IF: 27.203; D1
  - Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, Carson P, Anand I, Doehner W, Haass M, Komajda M, Miller A, Pehrson S, Teerlink JR, Schnaidt S, Zeller C, Schnee JM, Anker SD, (López-Sendón JL). Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction EMPEROR-Preserved Trial. *Circulation*. 2021; 144(16): 1284-94. Article. IF: 39.918; D1
  - Pascual-Tejerina V, Sánchez-Recalde A, Gutiérrez-Larraya F, Ruiz-Cantadord J, Rodríguez-Padial L, Zamorano JL. Transcatheter closure of a vertical vein in a patient with total anomalous pulmonary venous drainage decompressing the left atrium with an AFR device. *Rev Esp Cardiol*. 2021; 74(11): 990-1. Letter. IF: 6.975; Q1
  - Peinado RP. Adherence to optimal ICD programming: an unresolved issue. *Rev Esp Cardiol*. 2021; 74(4): 286-9. Editorial Material. IF: 6.975; Q1
  - Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM, (López-Sendón JL). Cardiovascular events with finerenone in kidney disease and type 2 Diabetes. *New Engl J Med*. 2021; 385(24): 2252-63. Article. IF: 176.079; D1
  - Reynolds HR, Picard MH, Spertus JA, Peteiro J, Sendón JLL, Senior R, El-Hajjar MC, Celutkiene J, Shapiro MD, Pelliukka PA, Kunichoff DF, Anthopoulos R, Alfakih K, Abdul-Nour K, Khouri M, Bershtein L, De Belder M, Poh KK, Beltrame JF, Min JMK, Fleg JL, Li Y, Maron DJ, Hochman JS. Natural history of patients with ischemia and no obstructive coronary artery disease The CIAO-ISCHEMIA Study. *Circulation*. 2021; 144(13): 1008-23. Article. IF: 39.918; D1
  - Roca RF, Salado JCS, Fernández MC, Acuna JMG, Serrano AL, de Sa EL, Ramírez JR. Management of temperature control in post-cardiac arrest care: an expert report. *Med Intensiva*. 2021; 45(3): 164-74. Article. IF: 2.799; Q3
  - Rodríguez-Leor O, Cid-Alvarez B, de Prado AP, Rossello X, Ojeda S, Serrador A, López-Palop R, Martín-Moreiras J, Rumoroso JR, Cequier A, Ibáñez B, Cruz-González I, Romaguera R, Moreno R. In-hospital outcomes of COVID-19 ST-elevation myocardial infarction patients. *Eurointervention*. 2021; 16(17): 1426-33. Article. IF: 7.728; Q1
  - Romaguera R, Ojeda S, Cruz-González I, Moreno R. Spanish cardiac catheterization and coronary intervention registry. 30th Official Report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2020) in the year of the COVID-19 pandemic. *Rev Esp Cardiol*. 2021; 74(12): 1096-106. Article. IF: 6.975; Q1
  - Rubio-Alarcón M, Camara-Checa A, Dago M, Crespo-García T, Nieto-Marín P, Marín M, Merino JL, Toquero J, Salguero-Bodes R, Tamargo J, Cebrán J, Delpón E, Caballero R, Invest. *Zfhx3* transcription factor represses the expression of SCN5A gene and decreases sodium current density (I<sub>Na</sub>). *Int J Mol Sci*. 2021; 22(23): 13031. Article. IF: 6.208; Q1
  - RuiPérez-Campillo S, Castrejón S, Martínez M, Cervigón R, Meste O, Merino JL, Millet J, Castells F. Non-invasive characterisation of macroreentrant atrial tachycardia types from a vectorcardiographic approach with the slow conduction region as a cornerstone. *Comput Meth Prog Bio*. 2021; 200: 105932. Article. IF: 7.027; D1
  - Sabate M, Okkels-Jensen L, Tilsted HH, Moreno R, del Blanco BG, Macaya C, de Prado AP, Cequier A, Pérez-Fuentes P, Schutte D, Costa R, Stoll HP, Lassen JF. Thin- versus thick-strut polymer-free biolimus-eluting stents: the BioFreedom QCA randomised trial. *Eurointervention*. 2021; 17(3): 2 33-9. Article. IF: 7.728; Q1
  - Salamanca J, García-Guimaraes M, Camacho-Freire SJ, Ojeda S, Veiga G, Jiménez-Valero S, Hernández-Antolín R, Trillo R, Velazquez M, Cortes C, Gutiérrez-Barrios A, Franco-Pelaez JA, Lezcano-Pertejo C, Diez-Delhoyo F, Gamarrá A, Aguilar R, Diez-Villanueva P, Bastante T, Alfonso F. Spontaneous coronary artery dissection and Takotsubo syndrome: comparison of baseline clinical and angiographic characteristics and in-hospital outcomes. *Coronary Artery Dis*. 2021;32(6):509-516. Article. IF: 1.717; Q4
  - Salinas P, Gonzalo N, Moreno VH, Fuentes M, Santos-Martínez S, Fernández-Díaz JA, Amat-Santos IJ, Ojeda FB, Borrego JC, Cuesta J, Hernández JMD, Diego-Nieto A, Dubois D, Galeote G, Goicolea J, Gutiérrez A, Jiménez-Fernández M, Jiménez-Mazuecos J, Jurado A, Lacunza J, Lee DH, López M, Lozano F, Martín-Moreiras J, Martín-Yuste V, Millan R, Minana G, Mohandes M, Morales-Ponce FJ, Nunez J, Ojeda S, Pan M, Rivero F, Robles J, Rodríguez-Leiras S, Rojas S, Rondan J, Rumiz E, Sabate M, Sanchis J, Vaquerizo B, Escaned J. Choice of CTO scores to predict procedural success in clinical practice. A comparison of 4 different CTO PCI scores in a comprehensive national registry including expert and learning CTO operators. *Plos One*. 2021; 16(4): e0245898. Article. IF: 3.752; Q2
  - Samuel M, Tardif JC, Khairy P, Roubille F, Waters DD, Gregoire JC, Pinto FJ, Maggioni AP, Diaz R, Berry C, Koenig W, Ostadal P, López-Sendón J, Gamra H, Kiwan GS, Dube MP, Provencher M, Orfano A, Blondeau L, Kouz S, L'Allier PL, Ibrahim R, Bouabdallaoui N, Mitchell D, Guertin MC, Lelorier J. Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). *Eur Heart J Qual Care Clin Outcomes*. 2021; 7(5): 486-95. Article. IF: 7.064; Q1
  - Tamargo J, López-Sendón J. Ranolazine: a better understanding of pathophysiology and patient profile to guide treatment of chronic stable angina. *Future Cardiol*. 2021; 18(3): 235-51 . Review. Not Indexed
  - Tardif JC, Bouabdallaoui N, L'Allier PL, Gaudet D, Shah BI, Pillinger MH, López-Sendón J, da Luz P, Verret L, Audet S, Dupuis J, Denault A, Peltier M, Tessier PA, Samson S, Fortin D, Tardif JD, Busseuil D, Goulet E, Lacoste C, Dubois A, Joshi AY, Waters DD, Hsue P, Lepor NE, Lesage F, Sainturet N, Roy-Clavel E, Bassevitch Z, Orfano A, Stamatescu G, Gregoire JC, Busque L, Lavallee C, Hetu PO, Paquette JS, Deftereos SG, Levesque S, Cossette M, Nozza A, Chabot-Blanchet M, Dube MP, Guertin MC, Boivin G. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. *Lancet Respir Med* . 2021; 9(8): 924-32. Article. IF: 102.642; D1
  - Testa L, Agnifili M, Van Mieghem NM, Tchetché D, Asgar AW, De Backer O, Latib A, Reimers B, Stefanini G, Trani C, Colombo A, Giannini F, Bartorelli A, Wojakowski W, Dabrowski M, Jagielak D, Banning AP, Kharbanda R, Moreno R, Schofer J, van Royen N, Pinto D, Serra A, Segev A, Giordano A, Brambilla N, Rubbio AP, Casenghi M, Oreglia J, De Marco F, Tanja R, McCabe JM, Abzaid A, Voskuil M, Teles R, Zoccali GB, Bianchi G, Sondergaard L, Bedogni F. Transcatheter aortic valve replacement for degenerated transcatheter aortic valves The TRANSIT International Project. *Circ Cardiovasc Inte*. 2021; 14(6) :628-38. Article. IF: 7.514; Q1
  - Trejo-Velasco B, Tello-Montoliu A, Cruz-González I, Moreno R, Baz-Alonso JA, Salvadorés PJ, Romaguera R, Molina-Navarro E, Paredes-Galán E, Fernández-Barbeira S, Ortiz-Saez A, Bastos-Fernández G, de Miguel-Castro A, Figueiras-Guzmán A, Íñiguez-Romo A, Jiménez-Díaz VA. Impact of comorbidities and antiplatelet regimen on platelet reactivity levels in patients undergoing transcatheter aortic valve implantation. *J Cardiovasc Pharm*. 2021; 78(3): 463-73. Article. IF: 3.271; Q3
  - Vega JDS, Salinas GLA, Flórez JMV, Sole AA, de Sa EL, Ruiz RS, Palacios VB, Raposeiras-Roubin S, Varela SG, Sanchís J, Melchor LS, Martínez-Seara X, López LM, Gómez JLZ, Fernández MS. Temporal trends in postinfarction ventricular septal rupture: the CIVIAM Registry. *Rev Esp Cardiol*. 2021; 74(9): 757-64. Article. IF: 6.975; Q1
  - Vehmeijer JT, Koyak Z, Leerink JM, Zwinderman AH, Harris L, Peinado R, Oechslin EN, Robbers-Visser DE, Groenink M, Boekholdt SM, De Winter RJ, Oliver JM, Bouma BJ, Budts W, Van Gelder IC, Mulder BJM, de Groot JR. Identification of patients at risk of sudden cardiac death in congenital heart disease: The PROspEcTIVE study on implaNTable cardIOverter defibrillator therapy and suddEN cardiac death in Adults with Congenital Heart Disease (PREVENTION-ACHD). *Heart Rhythm*. 2021; 18(5): 785-92. Article. IF: 6.779; Q2
  - White HD, O'Brien SM, Alexander KP, Boden WE, Bangalore S, Li JH, Manjunath CN, López-Sendón JL, Peteiro J, Gosselin G, Berger JS, Maggioni AP, Reynolds HR, Hochman JS, Maron DJ. Comparison of days alive out of hospital with initial invasive vs conservative management a prespecified analysis of the ISCHEMIA Trial. *JAMA Cardiol*. 2021; 6(9): 1023-31. Article. IF: 30.154; D1

## Research projects

**Antorrena Miranda MI.** International study of comparative health effectiveness with medical and invasive approaches -



estudio internacional comparativo de la eficacia sanitaria con enfoques médicos e invasivos. New York University School Of Medicine. 2013-Ongoning.

Management centre: FIBHULP

**Galeote García G.** Aterectomia rotacional electiva vs de rescate en pacientes con lesiones coronarias calcificadas graves e insuficiencia renal crónica. Medtronic Ibérica S.A. 2020-Ongoning.

Management centre: FIBHULP

**Guzmán Martínez G.** Inmunidad en sars-cov-2 y riego cardiovascular. Cohorte prospectiva. FIBHULP. 2020-Ongoning.

Management centre: FIBHULP

**Guzmán Martínez G.** Marcadores precoces de disfunción ventricular derecha y alteraciones de la circulación pulmonar en pacientes afectos de hipertensión pulmonar. Siemens Healthcare S.L. 2018-Ongoning.

Management centre: FIBHULP

**Jiménez Valero S.** Análisis de correlación entre los marcadores de inflamación y morfología de placas coronarias mediante tomografía de coherencia óptica y tec multicorte: estudio IVI. Abbott Laboratories S.A. 2009-Ongoning.

Management centre: FIBHULP

**Jiménez Valero S.** Estudio en modelo porcino para evaluar la utilidad de la tomografía de coherencia óptica en el análisis de las lesiones endocárdicas producidas por radiofrecuencia. Medlumics S.L. 2015-Ongoning.

Management centre: FIBHULP

**López de Sá y Arese E.** Investigación traslacional en arritmias cardíacas hereditarias (S2017/BMD-3738). CM. 2018-

2021.

Management centre: FIBHULP

**López-Sendón Henstchel JL.** Biomarcadores en la cardiotoxicidad por agentes antineoplás: rendimiento dianóstico. Boehringer Ingelheim España S.A. 2015-Ongoning.

Management centre: FIBHULP

**López-Sendón Henstchel JL.** Colchicine cardiovascular outcome trial\_COLCOT. Montreal Heart Institute. 2017-Ongoning.

Management centre: FIBHULP

**López-Sendón Henstchel JL.** Colchicine coronavirus sars-cov2 trial (COCORONA-Covid-19). Montreal Heart Institute. 2020-Ongoning.

Management centre: FIBHULP

**López-Sendón Henstchel JL, Borobia Pérez AM.** A multicentre, adaptative, randomize controlled platform trial of the safety and efficacy of antithrombotic and additional estrategies in hospitalized adult with COVID-19. National Institute of Health. 2020-Ongoning.

Management centre: FIBHULP

**Merino Llorens JL.** Addressing multimorbidity in elderly atrial fibrillation patients through interdisciplinary, tailored, patient-centred care pathways (EHRA-PATHS). UE. 2020-2026.

Management centre: FIBHULP

**Merino Llorens JL.** El vectorcardiograma como herramienta de caracterización no invasiva de ia dinámica de activación y de i-a presencia y locauzación de zonas de conducción lenta en los circuitos de fijer auriculár atípico tzquierdo mediante vectorcardiograma. Arrhythmia Network Technology S.L. 2018-Ongoning.

Management centre: FIBHULP

**Merino Llorens JL.** Formacion en investigación en electrofisiología cardiaca. European Society Of Cardiology. 2015-Ongoning.

Management centre: FIBHULP

**Merino Llorens JL.** High radiofrequency power for faster and safer pulmonary veins ablation trial (Power FAST II) (PI18/01522). ISCIIL. 2019-2021.

Management centre: FIBHULP

**Merino Llorens JL.** High radiofrequency power for faste and safe pulmonary veins ablation-a pilot observational study (Power Fast I). Arrhythmia Network Trechnology S.L. 2018-Ongoning.

Management centre: FIBHULP

**Merino Llorens JL.** Hospital Smart development based on AI (HosmartAI). UE. 2020-2024.

Management centre: FIBHULP

**Merino Llorens JL.** Registro retrospectivo de identificación de factores cardiovasculares de mal pronóstico en pacientes covid-19 (CARD-COVID). Medtronic Ibérica S.A. 2020-Ongoning.

Management centre: FIBHULP

**Moreno Gómez JR.** Evaluacion clínica y seguimiento de los pacientes con cardiopatía estructural sometidos a procedimientos de tratamiento percutáneo. Abbott Laboratories S.A. 2011-Ongoning.

Management centre: FIBHULP

**Peinado Peinado R.** Comparacion de un cateter multielectrodo frente a un cateter de ablacion de punta irrigada para crear mapas de voltaje y activacion en pacientes con taquicardias auriculares macroreentrantes. Medtronic Ibérica S.A. 2019-Ongoning.

2019-Ongoning.

Management centre: FIBHULP

**Peinado Peinado R.** Influencia del remodelado eléctrico del miocardio auricular en la recurrencia de fibrilación auricular tras el aislamiento eléctrico de las venas pulmonares por fibrilación auricular paroxística. Abbott Medical España S.A. 2009-Ongoning.

Management centre: FIBHULP

**Peinado Peinado R.** Papel de los receptores del sistema inmune innato en el desarrollo y evolución de la fibrilación auricular. Medtronic Ibérica S.A. 2021-Ongoning.

Management centre: FIBHULP

**Peinado Peinado R.** PI-719 síndrome de apneas-hipopneas obstructivas del sueño y arritmias ventriculares en pacientes con disfunción ventricular sistólica portadores de DAI. Fundación Casa del Corazón. 2008-Ongoning.

Management centre: FIBHULP

**Peinado Peinado R.** Registro de pacientes con cardipatía congénita del adulto portadores de un sistema de terapia de resincronización cardiaca (RETRACCA). Abbott Medical España S.A. 2017-Ongoning.

Management centre: FIBHULP

**Peinado Peinado R.** Utilidad de los algoritmos de diagnostico diferencial electrocardiografico de las taquicardias regulares de QRS ancho en pacientes con cardiopatías congenitas de adulto. Medtronic Ibérica S.A. 2019-Ongoning.

Management centre: FIBHULP

**Riera del Moral LF.** Tratamiento celular de los aneurismas de aorta abdominal en



un modelo murino. Jotec Cardiovascular S.L. 2017-Ongong.

**Management centre:** FIBHULP

## Clinical trials

**Antorrena Miranda, MI.** Ensayo de fase III, aleatorizado y doble ciego para evaluar la eficacia y la seguridad de una dosis diaria de 10 mg de empagliflozina en comparación con placebo en pacientes con insuficiencia cardíaca crónica con fracción de eyección preservada (icc-fep).

**Type:** Clinical Trials, phase III.

**HULP code:** Appendix 2 4988.

**Sponsored by:** Boehringer Ingelheim International GmbH.

**Signed date:** 16/02/2021

**Antorrena Miranda, MI.** Ensayo en fase III, aleatorizado y doble ciego para evaluar la eficacia y la seguridad de una dosis diaria de 10 mg de empagliflozina en comparación con el placebo en pacientes con insuficiencia cardíaca crónica con fracción de eyección reducida (icc-fer).

**Type:** Clinical Trials, phase III.

**HULP code:** Appendix 2 5001.

**Sponsored by:** Boehringer Ingelheim International GmbH.

**Signed date:** 20/04/2021

**Armada Romero, E.** Perfil de ldl-c en pacientes con evento cardiovascular: un estudio multicentrico retrospectivo en españa. estudio heartbeat.

**Type:** Estudios, phase EPA-OD.

**HULP code:** PI-4500 DAI-LDL-2020-01.

**Sponsored by:** Daiichi Sankyo España.

**Signed date:** 15/01/2021

**Armada Romero, E.** Estudio en fase III, aleatorizado, doble ciego y controlado

con placebo para evaluar los efectos de dalcetrapib sobre el riesgo cardiovascular (cv) en una población definida genéticamente con síndrome coronario agudo reciente (sca): el ensayo dal-gene.

**Type:** Clinical Trials, phase III.

**HULP code:** Appendix 2 4627.

**Sponsored by:** Dalcor Pharma Uk Ltd.

**Signed date:** 03/02/2021

**Castro Conde, A.** Comparación del efecto de tirzepatida frente al de dulaglutida sobre los acontecimientos cardiovasculares mayores en pacientes con diabetes de tipo 2 (surpass-cvot).

**Type:** Clinical Trials, phase I.

**HULP code:** Appendix 1 5484.

**Sponsored by:** Lilly, S.A.

**Signed date:** 11/03/2021

**Escobar Cervantes, C.** Estudio epidemiológico multinacional transversal de pacientes hipertensos con dislipemia y resultados proporcionados por el paciente.

**Type:** Estudios, phase EPA-OD.

**HULP code:** PI-4893B SNAPSHOT.

**Sponsored by:** Laboratorios Servier, S.L.

**Signed date:** 19/10/2021

**Jiménez Valero, S.** Ensayo clínico aleatorizado para evaluar el efecto de los betabloqueantes y los antiagregantes plaquetarios en pacientes con disección espontánea de la arteria coronaria.

**Type:** Clinical Trials, phase IV.

**HULP code:** 5960 BA-SCAD.

**Sponsored by:** Sociedad Española De Cardiología (Sec).

**Signed date:** 16/08/2021

**López De Sá Arese, E.** Ensayo multicéntrico, adaptativo, aleatorizado y controlado sobre la seguridad y eficacia de

las estrategias antitrombóticas en adultos hospitalizados con COVID-19.

**Type:** Clinical Trials, phase IV.

**HULP code:** 5694 ACTIV-4-ACUTE.

**Sponsored by:** Fundacion Para La Investigacion Biomedica Hospital Universitario La Paz.

**Signed date:** 15/01/2021

**López De Sá Arese, E.** Estudio en fase IIb, aleatorizado, doble ciego controlado con placebo, de grupos paralelos para evaluar la eficacia y la seguridad de medi6570 en participantes con infarto de miocardio previo, inflamación persistente y niveles elevados de prohormona n-terminal natriurético cerebral.

**Type:** Clinical Trials, phase II.

**HULP code:** Appendix 1 5637.

**Sponsored by:** Astrazeneca Ab.

**Signed date:** 16/03/2021

**López De Sá Arese, E.** Estudio para la validación clínica de un nuevo biomarcador para determinar la predisposición a infecciones en pacientes con infarto agudo de miocardio.

**Type:** Estudios No EPA.

**HULP code:** pi-4791 BIOMIN-001.

**Sponsored by:** Crazy Science & Business Sl.

**Signed date:** 28/06/2021

**López De Sá Arese, E.** Estudio en fase IIb, aleatorizado, doble ciego controlado con placebo, de grupos paralelos para evaluar la eficacia y la seguridad de medi6570 en participantes con infarto de miocardio previo, inflamación persistente y niveles elevados de prohormona n-terminal natriurético cerebral.

**Type:** Clinical Trials, phase II.

**HULP code:** Appendix 2 5637.

**Sponsored by:** Astrazeneca Ab.

**Signed date:** 06/07/2021

**López De Sá Arese, E.** Estudio clínicofundamental de fase 3, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad del estimulador de la gcsvericiguat/mk-1242 en adultos con insuficiencia cardíaca crónica con fracción de eyección reducida.

**Type:** Clinical Trials, phase III.

**HULP code:** 5969 MK1242-035.

**Sponsored by:** Merck Sharp And Dohme De España, S.A.

**Signed date:** 06/09/2021

**López Fernández, T.** Epiq-affiniti ultrasound system study for cardiology.

**Type:** Estudios No EPA.

**HULP code:** Appendix 1 PI-2996.

**Sponsored by:** Philips Ultrasound Inc.

**Signed date:** 23/04/2021

**López Fernández, T.** Registro de la profilaxis cardioembólica de los pacientes con cáncer en tratamiento oncoespecífico.

**Type:** Estudios, phase EPA-OD.

**HULP code:** PI-4806 PROCECAN 2021.

**Sponsored by:** Fundacion Seth.

**Signed date:** 07/10/2021

**Moreno Gómez, JR.** Observational study to evaluate the clinical outcome of high-risk patients undergoing percutaneous coronary intervention (pci) with everolimus-elutingstent implantation using intracoronary tools for pci guidance and optimization.

**Type:** Estudios No EPA.

**HULP code:** PI-4898 OPTI-XIENCE.

**Sponsored by:** Fundación Casa Del Corazón.

**Signed date:** 30/08/2021



**Moreno Gómez, JR.** Ensayo clínico controladoaleatorizado para comparar la seguridad y eficacia del stentliberador de sirolimus, ultradelgado con polímerobiodgradable (supraflextm cruz), y el stent liberador deeverolimus, con polímero biodegradable (synergytm), en eltratamiento de la enfermedad de las arterias coronarias detres vasos. multivessel talent.

**Type:** Estudio Producto Sanitario.  
**HULP code:** 6029 TP1125.  
**Sponsored by:** Chansu Vascular Technologies, Llc.  
**Signed date:** 18/11/2021

**Moreno Gómez, JR.** Estudio aleatorizado paralelo para evaluar la utilidad de la revisión angiográfica rutinaria 6 meses después del intervencionismo percutáneo en el tronco común izquierdo. estudio angeline.

**Type:** Estudios No EPA.  
**HULP code:** 5928 NUIG-2020-002.  
**Sponsored by:** National University Of Ireland, Galway.  
**Signed date:** 15/09/2021

**Moreno Gómez, JR.** Primera investigación clínica en humanos del catéter para angioplastia coronaria transluminal percutánea recubierto de everolimus de chansu vascular technologies: evaluación clínica en el tratamiento de sujetos con reestenosis intrastent de lesiones de arterias coronarias tratadas previamente.

**Type:** Estudio Producto Sanitario.  
**HULP code:** 5979 ECRI 14.  
**Sponsored by:** European Cardiovascular Research Institute (Ecri-14).  
**Signed date:** 30/11/2021

**Moreno Gómez, JR.** Guía de ultrasonido intravascular para procedimientos complejos indicados como dealto riesgo (ivus chip).

**Type:** Estudios, phase EPA-OD.  
**HULP code:** 5979 ECRI 14.  
**Sponsored by:** European Cardiovascular Research Institute (Ecri-14).  
**Signed date:** 30/11/2021

**Moreno Gómez, JR.** Registro de dispositivos médicos vasculares de abbott (abbott vascular medical deviceregistry av-mdr).

**Type:** Estudio Producto Sanitario.  
**HULP code:** PI-5013 CRD-1008/ABT-CIP-10349.  
**Sponsored by:** Sjm International Inc.  
**Signed date:** 01/12/2021

**Moreno Gómez, JR.** Fractional flow reserve or 3d-quantitative-coronaryangiography based vessel-frr guided revascularization: fast III trial.

**Type:** Estudio Producto Sanitario.  
**HULP code:** 6036 ECRI-15.  
**Sponsored by:** European Cardiovascular Research Institute (Ecri-15).  
**Signed date:** 14/12/2021".

## ■ Patents and trademarks

**Filgueiras Rama D, López de Sá y Areses E, Millet Roig J, Calvo Saiz CJ,** inventors; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), FIBHULP, Universidad Politécnica de Valencia, assignees. Method of predicting or prognosticating neurological performance in patients who have suffered a cardiac arrest and optionally comatose status due to ventricular fibrillation. PCT/EP2015/076893, EP3020333; 2014 November 17.

**Riera del Moral LF,** inventor; FIBHULP, assignee. Aortic endoprosthesis for the treatment of aneurysm. P201231638, PCT/ES2013/070712; 2012 October 24.

**Castro Conde A,** author; FIBHULP, assignee. Trademark name: RECAR Programa de Rehabilitación Cardiaca; CM 18457042; 2021 April 20.

